Drugs and Hair Loss

Dermatologic Clinics

Volumn 31, Issue 1, 2013, Pages 67-73

  Patel, Mansi ^a   Harrison, Shannon ^b   Sinclair, Rodney ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Anagen effluivum; Chemotherapy induced alopecia; Drug induced alopecia; Hair loss; Telogen effluvium

Indexed keywords

ALKYLATING AGENT; ANDROGEN; ANTHRACYCLINE; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CARDIOVASCULAR AGENT; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; FLUOXETINE; LEVONORGESTREL; LITHIUM; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; MINOXIDIL; MONOAMINE OXIDASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PSYCHOTROPIC AGENT; RETINOID; RETINOL; SERTRALINE; TAXANE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VALPROIC ACID; VINCA ALKALOID;

ALOPECIA; ANAGEN ARREST; ANAGEN EFFLUVIUM; BLEEDING; CHILDBIRTH; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEVER; HAIR LOSS; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LOW DRUG DOSE; MALE TYPE ALOPECIA; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; STRESS; TELOGEN EFFLUVIUM;

ALOPECIA; FEMALE; HAIR; HAIR FOLLICLE; HUMANS; MALE; PHARMACEUTICAL PREPARATIONS;

EID: 84869183821     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2012.08.002     Document Type: Review

References (64)

1. Harrison S., Sinclair R. Telogen effluvium. Clin Exp Dermatol 2002, 27(5):389-395.
2. Kligman A.M. The human hair cycle. J Invest Dermatol 1959, 33:307-316.
3. Whiting D.A. Chronic telogen effluvium. Dermatol Clin 1996, 14(4):723-731.
4. Paus R., Cotsarelis G. The biology of hair follicles. N Engl J Med 1999, 341(7):491-497.
5. Harrison S., Bergfeld W. Diffuse hair loss: its triggers and management. Cleve Clin J Med 2009, 76(6):361-367.
6. Gordon K.A., Tosti A. Alopecia: evaluation and treatment. Clin Cosmet Investig Dermatol 2011, 4:101-106.
7. Blume-Peytavi U., Blumeyer A., Tosti A., et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol 2011, 164(1):5-15.
8. Pillans P.I., Woods D.J. Drug-associated alopecia. Int J Dermatol 1995, 34(3):149-158.
9. Mercke Y., Sheng H., Khan T., et al. Hair loss in psychopharmacology. Ann Clin Psychiatry 2000, 12(1):35-42.
10. Yun S.J., Kim S.J. Hair loss pattern due to chemotherapy-induced anagen effluvium: a cross-sectional observation. Dermatology 2007, 215(1):36-40.
11. Trueb R.M. Chemotherapy-induced alopecia. Semin Cutan Med Surg 2009, 28(1):11-14.
12. Trueb R.M. Chemotherapy-induced anagen effluvium: diffuse or patterned?. Dermatology 2007, 215(1):1-2.
13. Tosti A., Piraccini B.M., Vincenzi C., et al. Permanent alopecia after busulfan chemotherapy. Br J Dermatol 2005, 152(5):1056-1058.
14. Koppel R.A., Boh E.E. Cutaneous reactions to chemotherapeutic agents. Am J Med Sci 2001, 321(5):327-335.
15. Espinosa E., Zamora P., Feliu J., et al. Classification of anticancer drugs-a new system based on therapeutic targets. Cancer Treat Rev 2003, 29(6):515-523.
16. Selleri S., Arnaboldi F., Vizzotto L., et al. Epithelium-mesenchyme compartment interaction and oncosis on chemotherapy-induced hair damage. Lab Invest 2004, 84(11):1404-1417.
17. Duvic M., Lemak N.A., Valero V., et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol 1996, 35(1):74-78.
18. Tosti A., Pazzaglia M. Drug reactions affecting hair: diagnosis. Dermatol Clin 2007, 25(2):223-231.
19. Grevelman E.G., Breed W.P. Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 2005, 16(3):352-358.
20. Tosti A., Piraccini B.M., Sisti A., et al. Hair loss in women. Minerva Ginecol 2009, 61(5):445-452.
21. Gilmore S., Sinclair R. Chronic telogen effluvium is due to a reduction in the variance of anagen duration. Australas J Dermatol 2010, 51(3):163-167.
22. Mortimer P.S., Dawber R.P. Hair loss and lithium. Int J Dermatol 1984, 23(9):603-604.
23. Orwin A. Hair loss following lithium therapy. Br J Dermatol 1983, 108(4):503-504.
24. Mccreadie R.G., Morrison D.P. The impact of lithium in South-west Scotland. I. Demographic and clinical findings. Br J Psychiatry 1985, 146:70-74.
25. Dawber R., Mortimer P. Hair loss during lithium treatment. Br J Dermatol 1982, 107(1):124-125.
26. Jeavons P.M., Clark J.E. Sodium valproate in treatment of epilepsy. Br Med J 1974, 2(5919):584-586.
27. Despland P.A. Praxis (Bern 1994) 1994, 83(40):1132-1139. [in French].
28. Henriksen O., Johannessen S.I. Clinical and pharmacokinetic observations on sodium valproate-a 5-year follow-up study in 100 children with epilepsy. Acta Neurol Scand 1982, 65(5):504-523.
29. Egger J., Brett E.M. Effects of sodium valproate in 100 children with special reference to weight. Br Med J (Clin Res Ed) 1981, 283(6291):577-581.
30. Ogilvie A.D. Hair loss during fluoxetine treatment. Lancet 1993, 342(8884):1423.
31. Rais T., Singh T., Rais A. Hair loss associated with long-term sertraline treatment in teenager. Psychiatry (Edgmont) 2005, 2(7):52.
32. Warnock J.K. Psychotropic medication and drug-related alopecia. Psychosomatics 1991, 32(2):149-152.
33. Wang Y.Y., Po H.L. Enoxaparin-induced alopecia in patients with cerebral venous thrombosis. J Clin Pharm Ther 2006, 31(5):513-517.
34. Barnes C., Deidun D., Hynes K., et al. Alopecia and dalteparin: a previously unreported association. Blood 2000, 96(4):1618-1619.
35. Apsner R., Horl W.H., Sunder-Plassmann G. Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulation. Blood 2001, 97(9):2914-2915.
36. Sarris E., Tsele E., Bagiatoudi G., et al. Diffuse alopecia in a hemodialysis patient caused by a low molecular- weight heparin, tinzaparin. Am J Kidney Dis 2003, 41(5):E15.
37. Nagao T., Ibayashi S., Fujii K., et al. Treatment of warfarin-induced hair loss with ubidecarenone. Lancet 1995, 346(8982):1104-1105.
38. Umlas J., Harken D.E. Warfarin-induced alopecia. Cutis 1988, 42(1):63-64.
39. Graeber C.W., Lapkin R.A. Metoprolol and alopecia. Cutis 1981, 28(6):633-634.
40. Hilder R.J. Propranolol and alopecia. Cutis 1979, 24(1):63-64.
41. Scribner M.D. Propranolol therapy. Arch Dermatol 1977, 113(9):1303.
42. Martin C.M., Southwick E.G., Maibach H.I. Propranolol induced alopecia. Am Heart J 1973, 86(2):236-237.
43. Leaker B., Whitworth J.A. Alopecia associated with captopril treatment. Aust N Z J Med 1984, 14(6):866.
44. Samuel L.M., Davie M., Starkey I.R. Amiodarone and hair loss. Postgrad Med J 1992, 68(803):771.
45. Mcgovern B., Garan H., Kelly E., et al. Adverse reactions during treatment with amiodarone hydrochloride. Br Med J (Clin Res Ed) 1983, 287(6386):175-180.
46. Hair loss and contraceptives. Br Med J 1973, 2(5865):499-500.
47. Se W. Comprehensive dermatological drug therapy 2007, Saunders Elsevier, p. 431.
48. Seckin D., Yildiz A. Repigmentation and curling of hair after acitretin therapy. Australas J Dermatol 2009, 50(3):214-216.
49. Gupta K.B., Kumar V., Vishvkarma S., et al. Isoniazid-induced alopecia. Lung India 2011, 28(1):60-61.
50. Fitzgerald J.M., Turner M.T., Dean S., et al. Alopecia side effect of antituberculosis drugs. Lancet 1996, 347(8999):472.
51. Harry T.C., Matthews M., Salvary I. Indinavir use: associated reversible hair loss and mood disturbance. Int J STD AIDS 2000, 11(7):474-476.
52. Ginarte M., Losada E., Prieto A., et al. Generalized hair loss induced by indinavir plus ritonavir therapy. AIDS 2002, 16(12):1695-1696.
53. Mirena Product information leaflet 2009, Bayer HealthCare Pharmaceuticals.
54. Garcovich S., Manco S., Zampetti A., et al. Onset of lichen planopilaris during treatment with etanercept. Br J Dermatol 2008, 158(5):1161-1163.
55. Abbasi N.R., Orlow S.J. Lichen planopilaris noted during etanercept therapy in a child with severe psoriasis. Pediatr Dermatol 2009, 26(1):118.
56. Handa S., Sahoo B. Childhood lichen planopilaris: a study of 87 cases. Int J Dermatol 2001, 40:461.
57. Fernandez-Torres R., Paradela S., Valbuna L., et al. Infliximab-induced lichen planopilaris. Ann Pharmacol 2010, 44:1501-1503.
58. Rosman H.S., Anadkat M.J. Tufted hair follicultis in a woman treated with trastuzumab. Target Oncol 2010, 5:295-296.
59. Myskowski P.L., Halpern A.C. Skin reactions to the new biologic anticancer drugs. Curr Opin Support Palliat Care 2009, 3:294-299.
60. Graves J.E., Jones B.F., Lind A.C., et al. Nonscarring alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J Am Acad Dermatol 2006, 55:349-353.
61. Donovan J.C., Ghazarian D.M., Shaw J.C. Scarring Alopecia Associated with use of the epidermal growth factor receptor inhibitor gefitinib. Arch Dermatol 2008, 144(11):1524-1525.
62. Hepper D.M., Wu P., Anadkat M.J. Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. J Acad Dermatol 2011, 64(5):996-998.
63. Hoekzema R., Drillenburg P. Folliculitis decalvans associated with erlotinib. Clin Exp Dermatol 2010, 35:916-918.
64. Ena P., Fadda G.M., Ena L., et al. Tufted hair folliculitis in a woman treated with lapatinib for breast cancer. Clin Exp Dermatol 2008, 33:776-794.